非小细胞肺癌58例表皮生长因子受体突变状态

摘要

Objective To investigate the value of gene mutation status of epidermal growth factor receptor(EGFR) in predicting the sensitivity of non-small cell lung cancer(NSCLC) to tyrosine kinase inhibitors(TKIs) therapy. Methods Fifty-eight fresh specimens of lung cancer tissues(group A) and normal lung tissues (group B) were collected from 58 NSCLC patients. DNA was extracted from lung cancer tissues and normal lung tissues. Exon 19 and 21 EGFR genes were amplified by PCR. Results The EGFR gene in group B was wild type. The mutation rate of group A was 32. 8%, which was 73. 7% for exon 19,and 26. 3% for exon 21. The EGFR gene mutation in group A was significantly more frequent in adenocarcinoma, female and nonsmoker than that in squamous carcinoma,male and smoker. The patients were followed up for 3.0-29.3 months with a median survival time of 23. 5 months. Three of 19 cases with gene mutation were undergoing TKIs therapy, who were survival during follow up. Conclusion In the patients with NSCLC, the mutation of exon 19 is the most common type and the mutation occurs more frequently in adenocarcinoma,female,and non-smoker. Detection of EGFR gene mutation is valuable in predicting the sensitivity of NSCLC to the treatment of TKIs.%目的 探讨非小细胞肺癌(NSCLC)表皮生长因子受体(EGFR)突变状态及其对预测酪氨酸激酶抑制剂(TKIs)疗效的价值.方法 提取58例NSCLC患者肿瘤组织和正常肺组织的DNA,用巢式PCR扩增,直接测序法检测EGFR外显子19和21基因突变.结果 正常肺组织中EGFR基因均为野生型.肿瘤组织EGFR基因突变率为32.8％(19/58),外显子19和21突变率分别为73.7％(14/19)和26.3％00(5/19).腺癌、女性、不吸烟患者突变率要高于鳞癌、男性、吸烟患者(P＜0.05).随访3.0-29.3个月；58例患者的中位生存时间为23.5个月.19例EGFR基因突变者中,3例应用TKIs治疗,均健在.结论 NSCLC患者中,19外显子是EGFR基因突变的主要类型,女性、腺癌、不吸烟患者突变率较高.检测EGFR基因突变状态可用于预测NSCLC患者对TKIs治疗的敏感性.